Adverse Effects of Antiepileptic Drugs

 

 Buy Article Permissions and Reprints

ABSTRACT

Adverse effects of antiepileptic drugs (AEDs) are considered by patients to be at least as important as repetitive seizures in terms of quality of life. AED toxicity is frequent and contributes to a high proportion of treatment failures. Despite its high prevalence and clinical relevance, screening for adverse reactions to AEDs is not systematically included in everyday clinical practice; therefore it is very likely that it remains underestimated. Because there is little difference among AEDs in terms of efficacy, drug selection is often based on the adverse effects profile. AED toxicity is classified according to different parameters, such as severity, time of occurrence, organ system involvement, and mechanisms of action. Although most toxic reactions to drugs can be predicted from cumulative experience, prevention is not always possible, since multiple mechanisms and individual susceptibility to each drug participate in the final outcome. However, adverse effects can be reduced and appropriate action can be taken in time by means of a high degree of suspicion, knowledge of risk factors, and close follow-up. This article highlights factors to consider for detecting and managing AED adverse effects.

REFERENCES

• 1 Fisher R S, Vickrey B G, Gibson P et al.. The impact of epilepsy from the patient's perspective II: views about therapy and health care.  Epilepsy Res. 2000;  41 53-61
  CrossrefPubMedGoogle Scholar
• 2 Baker G A, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study.  Epilepsia. 1997;  38 353-362
  CrossrefPubMedGoogle Scholar
• 3 Gilliam F G, Fessler A J, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.  Neurology. 2004;  62 23-27
  PubMedGoogle Scholar
• 4 Perucca E, Meador K J. Adverse effects of antiepileptic drugs.  Acta Neurol Scand Suppl. 2005;  181 30-35
  PubMedGoogle Scholar
• 5 Rowan A J, Ramsay R E, Collins J F et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.  Neurology. 2005;  64 1868-1873
  CrossrefPubMedGoogle Scholar
• 6 Deckers C LP, Hekster Y A, Keyser A, Van Lier H J, Meinardi H, Renier W O. Monotherapy vs polytherapy for epilepsy: a multicentre double-blind randomised study.  Epilepsia. 2001;  42 1387-1394
  CrossrefPubMedGoogle Scholar
• 7 Meador K J. Cognitive and memory effects of the new antiepileptic drugs.  Epilepsy Res. 2006;  68 63-67
  CrossrefPubMedGoogle Scholar
• 8 Gilliam F G, Veloso F, Bomhof M AM et al.. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy.  Neurology. 2003;  60 196-202
  PubMedGoogle Scholar
• 9 Kanner A M, Wuu J, Faught E, Tatum IV W O, Fix A, French J A. the PADS Investigators . A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.  Epilepsy Behav. 2003;  4 548-552
  CrossrefPubMedGoogle Scholar
• 10 Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs.  Epilepsia. 2007;  48 1223-1244
  CrossrefPubMedGoogle Scholar
• 11 Arif H, Buchsbaum R, Weintraub D et al.. Comparison and predictors of rash associated with 15 antiepileptic drugs.  Neurology. 2007;  68 1701-1709
  CrossrefPubMedGoogle Scholar
• 12 Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability.  Epilepsia. 2007;  48 1360-1365
  CrossrefPubMedGoogle Scholar
• 13 Hirsch L J, Weintraub D B, Buchsbaum R et al.. Predictors of lamotrigine-associated rash.  Epilepsia. 2006;  47 318-322
  CrossrefPubMedGoogle Scholar
• 14 Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.  Neurology. 2005;  64 1134-1138
  PubMedGoogle Scholar
• 15 Pellock J M, Faught E, Leppik I E, Shinnar S, Zupanc M L. Felbamate: consensus of current clinical experience.  Epilepsy Res. 2006;  71 89-101
  CrossrefPubMedGoogle Scholar
• 16 Ibáñez L, Vidal X, Ballarín E, Laporte J R. Population-based drug-induced agranulocytosis.  Arch Intern Med. 2005;  165 869-874
  CrossrefPubMedGoogle Scholar
• 17 Levinson D F, Devinsky O. Psychiatric adverse events during vigabatrin therapy.  Neurology. 1999;  53 1503-1511
  PubMedGoogle Scholar
• 18 Mula M, Trimble M R, Lhatoo S D, Sander J W. Topiramate and psychiatric adverse events in patients with epilepsy.  Epilepsia. 2003;  44 659-663
  CrossrefPubMedGoogle Scholar
• 19 Mula M, Trimble M R, Yuen A, Liu R S, Sander J W. Psychiatric adverse events during levetiracetam therapy.  Neurology. 2003;  61 704-706
  PubMedGoogle Scholar
• 20 Chaves J, Sander J W. Seizure aggravation in idiopathic generalized epilepsies.  Epilepsia. 2005;  46(suppl 9) 133-139
  CrossrefPubMedGoogle Scholar
• 21 Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.  Brain. 2006;  129 1281-1292
  CrossrefPubMedGoogle Scholar
• 22 Genton P. When antiepileptic drugs aggravate epilepsy.  Brain Dev. 2000;  22 75-80
  CrossrefPubMedGoogle Scholar
• 23 Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures.  Epilepsia. 1998;  39 5-17
  CrossrefPubMedGoogle Scholar
• 24 Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy.  Epilepsia. 1998;  39 508-512
  CrossrefPubMedGoogle Scholar
• 25 Wakai S, Ito N, Sueoka H, Kawamoto Y, Hayasaka H, Chiba S. Severe myoclonic epilepsy in infancy and carbamazepine.  Eur J Pediatr. 1996;  155 724
  CrossrefPubMedGoogle Scholar
• 26 Corda D, Gelisse P, Genton P, Dravet C, Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes.  Epilepsia. 2001;  42 754-759
  CrossrefPubMedGoogle Scholar
• 27 Cerminara C, Montanaro M L, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy.  Neurology. 2004;  63 373-375
  CrossrefPubMedGoogle Scholar
• 28 Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential?.  CNS Drugs. 2003;  17 633-640
  CrossrefPubMedGoogle Scholar
• 29 Pellock J M, Wilder B J, Deaton R, Sommerville K W. Acute pancreatitis coincident with valproate use: a critical review.  Epilepsia. 2002;  43 1421-1424
  CrossrefPubMedGoogle Scholar
• 30 Fraunfelder F W, Fraunfelder F T, Keates E U. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma.  Ophthalmology. 2004;  111 109-111
  CrossrefPubMedGoogle Scholar
• 31 Drory V E, Korczyn A D. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants.  Clin Neuropharmacol. 1993;  16 19-29
  PubMedGoogle Scholar
• 32 Biton V, Mirza W, Montouris G, Vuong A, Hammer A E, Barrett P S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.  Neurology. 2001;  56 172-177
  CrossrefPubMedGoogle Scholar
• 33 Ben-Menachem E, Axelsen M, Johanson E H, Stagge A, Smith U L. Predictors of weight loss in adults with topiramate-treated epilepsy.  Obes Res. 2003;  11 556-562
  CrossrefPubMedGoogle Scholar
• 34 Reife R, Pledger G, Wu S C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults.  Epilepsia. 2000;  41(suppl 1) S66-S71
  PubMedGoogle Scholar
• 35 Sato Y, Kondo I, Ishida S et al.. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy.  Neurology. 2001;  57 445-449
  CrossrefPubMedGoogle Scholar
• 36 Ensrud K E, Walczak T S, Blackwell T, Ensrud E R, Bowman P J, Stone K L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study.  Neurology. 2004;  62 2051-2057
  PubMedGoogle Scholar
• 37 Petty S J, Paton L M, O'Brien T J et al.. Effect of antiepileptic medication on bone mineral measures.  Neurology. 2005;  65 1358-1365
  CrossrefPubMedGoogle Scholar
• 38 Andress D L, Ozuna J, Tirschwell D et al.. Antiepileptic drug-induced bone loss in young male patients who have seizures.  Arch Neurol. 2002;  59 781-786
  CrossrefPubMedGoogle Scholar
• 39 Chen S S, Shen M R, Chen T J, Lai S L. Effects of antiepileptic drugs on sperm motility of normal controls and epileptic patients with long-term therapy.  Epilepsia. 1992;  33 149-153
  CrossrefPubMedGoogle Scholar
• 40 Isojärvi J IT, Löfgren E, Juntunen K ST et al.. Effect of epilepsy and antiepileptic drugs on male reproductive health.  Neurology. 2004;  62 247-253
  CrossrefPubMedGoogle Scholar
• 41 Herzog A G, Drislane F W, Schomer D L et al.. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy.  Neurology. 2005;  65 1016-1020
  CrossrefPubMedGoogle Scholar
• 42 Gil-Nagel A, Lopez-Munoz F, Serratosa J M, Moncada I, Garcia-Garcia P, Alamo C. Effect of lamotrigine on sexual function in patients with epilepsy.  Seizure. 2006;  15 142-149
  CrossrefPubMedGoogle Scholar
• 43 Duncan S. Polycystic ovarian syndrome in women with epilepsy: a review.  Epilepsia. 2001;  42 60-65
  CrossrefPubMedGoogle Scholar
• 44 Isojärvi J IT, Taubøll E, Pakarinen A J et al.. Altered ovarian function and cardiovascular risk factors in valproate treated women.  Am J Med. 2001;  111 290-296
  CrossrefPubMedGoogle Scholar
• 45 Mikkonen K, Vainionpää L K, Pakarinen A J et al.. Long-term female reproductive endocrine health in young women with epilepsy during puberty.  Neurology. 2004;  62 445-450
  CrossrefPubMedGoogle Scholar
• 46 Vainionpää L K, Rättyä J, Knip M et al.. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy.  Ann Neurol. 1999;  45 444-450
  CrossrefPubMedGoogle Scholar
• 47 Isojärvi J I, Rättyä J, Myllylä V V et al.. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy.  Ann Neurol. 1998;  43 446-451
  CrossrefPubMedGoogle Scholar
• 48 McDonagh J, Stephen L J, Dolan F M et al.. Peripheral retinal dysfunction in patients taking vigabatrin.  Neurology. 2003;  61 1690-1694
  PubMedGoogle Scholar
• 49 Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence.  Epilepsia. 2001;  42 609-615
  CrossrefPubMedGoogle Scholar
• 50 De Marcos F A, Ghizoni E, Kobayashi E, Li L M, Cendes F. Cerebellar volume and long-term use of phenytoin.  Seizure. 2003;  12 312-315
  CrossrefPubMedGoogle Scholar
• 51 Holmes L B, Harvey E A, Coull B A et al.. The teratogenicity of anticonvulsant drugs.  N Engl J Med. 2001;  344 1132-1138
  CrossrefPubMedGoogle Scholar
• 52 Pennell P B. The importance of monotherapy in pregnancy.  Neurology. 2003;  60 S31-S38
  CrossrefPubMedGoogle Scholar
• 53 Vajda F J, Eadie M J. Maternal valproate dosage and fetal malformations.  Acta Neurol Scand. 2005;  112 137-143
  CrossrefPubMedGoogle Scholar
• 54 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
  CrossrefPubMedGoogle Scholar
• 55 Morrow J, Russell A, Guthrie E et al.. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
  CrossrefPubMedGoogle Scholar
• 56 Holmes L B, Wyszynski D F, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience.  Arch Neurol. 2004;  61 673-678
  CrossrefPubMedGoogle Scholar
• 57 Tomson T, Battino D, Bonizzoni E et al.. EURAP: an international registry of antiepileptic drugs and pregnancy.  Epilepsia. 2004;  45 1463-1464
  CrossrefPubMedGoogle Scholar
• 58 Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
  CrossrefPubMedGoogle Scholar
• 59 Cunnington M, Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Lamotrigine and the risk of malformations in pregnancy.  Neurology. 2005;  64 955-960
  CrossrefPubMedGoogle Scholar
• 60 Adab N, Kini U, Vinten J et al.. The longer term outcome of children born to mothers with epilepsy.  J Neurol Neurosurg Psychiatry. 2004;  75 1575-1583
  CrossrefPubMedGoogle Scholar
• 61 Eriksson K, Viinikainen K, Monkkonen A et al.. Children exposed to valproate in utero: population-based evaluation of risks and confounding factors for long-term neurocognitive development.  Epilepsy Res. 2005;  65 189-200
  CrossrefPubMedGoogle Scholar
• 62 Gaily E, Kantola-Sorsa E, Hiilesmaa V et al.. Normal intelligence in children with prenatal exposure to carbamazepine.  Neurology. 2004;  62 28-32
  CrossrefPubMedGoogle Scholar
• 63 Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker G A. Liverpool and Manchester Neurodevelopment Study Group . Neuropsychological effects of exposure to anticonvulsant medication in utero.  Neurology. 2005;  64 949-954
  CrossrefPubMedGoogle Scholar
• 64 Singh G, Driever P H, Sander J W. Cancer risk in people with epilepsy: the role of antiepileptic drugs.  Brain. 2005;  128 7-17
  PubMedGoogle Scholar
• 65 Lamminpää A, Pukkala E, Teppo L, Neuvonen P J. Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients.  Eur J Clin Pharmacol. 2002;  58 137-141
  CrossrefPubMedGoogle Scholar
• 66 Adelöw C, Ahlbom A, Feychting M, Jonson F, Schwartzbaum J, Tomson T. Epilepsy as a risk factor for cancer.  J Neurol Neurosurg Psychiatry. 2006;  77 784-786
  CrossrefPubMedGoogle Scholar
• 67 Olsen J H, Schulgen G, Boice J D et al.. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma.  Cancer Res. 1995;  55 294-297
  PubMedGoogle Scholar
• 68 Patsalos P N, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.  Lancet Neurol. 2003;  2 347-356
  CrossrefPubMedGoogle Scholar
• 69 French J A, Barry E G. Antiepileptic drug interactions.  Epilepsia. 2000;  41(suppl 8) S30-S36
  PubMedGoogle Scholar
• 70 Kanner A M, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.  Neurology. 2000;  55 588-591
  CrossrefPubMedGoogle Scholar

Antonio Gil-NagelM.D. 

Department of Neurology, Epilepsy Program, Hospital Ruber Internacional

La Masó 38, Mirasierra, 28034 Madrid, Spain

Email: agnagel@ruberinternacional.es